Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study

Summary Chimeric antigen receptor T (CAR‐T) cell therapy is highly effective in inducing complete remission in haematological malignancies. Severe cytokine release syndrome (CRS) is the most significant and life‐threatening adverse effect of this therapy. This multi‐centre study was conducted at six...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2023-08, Vol.202 (3), p.517-524
Hauptverfasser:	Zhou, Linghui, Fu, Weijun, Wu, Shenghao, Xu, Kailin, Qiu, Lugui, Xu, Yang, Yan, Xiaojing, Zhang, Qing, Zhang, Mingming, Wang, Linqin, Hong, Ruimin, Chang, Alex H., Yu, Jian, Fu, Shan, Kong, Delin, Li, Lu, Wang, Ying, Li, Zhenyu, Jiang, Huawei, Huang, Jing, Liu, Zhi, Su, Na, Wei, Guoqing, Hu, Yongxian, Huang, He
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia CAR‐T cell therapy Cell therapy Chimeric antigen receptors cytokine release syndrome Cytokine Release Syndrome - drug therapy Cytokines early prediction haematological malignancies Hematologic Neoplasms - therapy Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Lymphocytes T Lymphoma, Non-Hodgkin - drug therapy Malignancy Multiple myeloma Multiple Myeloma - drug therapy Non-Hodgkin's lymphoma Patients Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Receptors, Chimeric Antigen - therapeutic use Remission
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!